Company Overview and News

 
Macmahon Holdings Limited (MCHHF) CEO Michael Finnegan on Q4 2018 Results - Earnings Call Transcript

2018-08-24 seekingalpha
Ladies and gentlemen, thank you for standing by, and welcome to the Macmahon Holdings Limited 2018 Full Year Results Presentation. At this time, all participants are in a listen-only model. There will be a presentation followed by a question-and-answer session. [Operator instructions] I must advice you, that this conference is being recorded today, Friday 24 of August 2018.
MCHHF MAH

 
Profit lift for mining services stocks

2018-08-24 businessnews.com.au
Macmahon Holdings has posted strong profit growth for the year to June, adding to a string of good results for local mining services companies, including Lycopodium and NRW Holdings.
MCHHF NWH MAH

 
WA mining services boost FY18 profit

2018-08-24 businessnews.com.au
Macmahon Holdings has posted strong profit growth for the year to June, adding to a string of good results for local mining services companies, including Lycopodium and NRW Holdings.
MCHHF NWH MAH

 
Linking veterans to new opportunities

2018-07-05 businessnews.com.au
Veterans’ recruitment organisation Working Spirits is steadily increasing its profile among the Western Australian businesses community, with 10 former veterans recently finding placements, including with mining services business Macmahon Holdings.
MCHHF MAH

 
Ausdrill names new MD/CEO

2018-06-18 australianmining.com.au
Mark Norwell has been appointed as Ausdrill’s next managing director and chief executive officer to replace Ron Sayers.
MCHHF MAH

 
Macmahon Holdings starts phase II of Batu Hijau mining contract

2018-04-19 proactiveinvestors.com.au
Macmahon Holdings Limited (ASX:MAH) has started phase II of the mining contract for PT Amman Mineral Nusa Tenggara (AMNT) at the Batu Hijau Copper-Gold Project in Indonesia.
MCHHF MAH

 
Board Moves: John Gillam, Kim Horne

2018-03-27 businessnews.com.au
Former Bunnings managing director John Gillam has been named as the incoming chairman of building products company CSR while Macmahon Holdings has bolstered its board by recruiting former Alcoa of Australia executive Kim Horne.
MCHHF MAH

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:MAH / MACMAHON HOLDINGS LIMITED on message board site Silicon Investor.

Sign Petition to Keep Bill Maheru0027s Politically Incorrect Sign Petition to Keep Bill Maheru0027s Politically Incorrect Sign Petition to Keep Bill Maheru0027s Politically Incorrect DEBIQ - If Debbie Reynolds Married Vince McMahon... DEBIQ - If Debbie Reynolds Married Vince McMahon... DEBIQ - If Debbie Reynolds Married Vince McMahon...